Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amgen
(NQ:
AMGN
)
319.02
+1.34 (+0.42%)
Streaming Delayed Price
Updated: 12:38 PM EDT, Oct 9, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Amgen
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
2 Biotech Stocks to Buy Hand Over Fist in October
Today 10:15 EDT
These longtime leading biotech stocks still have plenty of upside ahead.
Via
The Motley Fool
Want to Invest in the Weight Loss Boom? Consider Buying These 2 Stocks
October 08, 2024
Investing in the most popular players in the space isn't the only valid approach.
Via
The Motley Fool
3 Magnificent Dividend Stocks to Buy in October
October 06, 2024
These dividend stocks are great picks as the fall season gets underway.
Via
The Motley Fool
Should You Buy the Dip on This Top Growth Stock?
October 05, 2024
The biotech needs to overcome an issue most drugmakers face at some point.
Via
The Motley Fool
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer
October 04, 2024
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention.
Via
Investor's Business Daily
(AMGN) - Analyzing Amgen's Short Interest
September 30, 2024
Via
Benzinga
Analyst Expectations For Amgen's Future
September 25, 2024
Via
Benzinga
Market Whales and Their Recent Bets on AMGN Options
September 24, 2024
Via
Benzinga
What the Options Market Tells Us About Amgen
September 23, 2024
Via
Benzinga
Eli Lilly Leads S&P Health Care Stocks With 1,241% Gain. But The Others Aren't Slackers.
October 03, 2024
Eli Lilly has gained markedly over the past decade. But it's not the only S&P 500 health care stock to notch a bullish gain.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Federal Judge Rules Amgen Must Face Tax Liability Lawsuit That Alleges Reckless Concealment Of $10.7B Tax Bill
October 02, 2024
Amgen faces a class-action lawsuit over allegations of concealing a $10.7 billion tax dispute with the IRS, with shareholders accusing the company of delaying critical disclosures. A federal judge...
Via
Benzinga
Topics
Lawsuit
Exposures
Financial
Legal
AskSlim Market Week - Friday, Sep. 27
September 27, 2024
An analysis and commentary on the financial markets.
Via
Talk Markets
Stock Market Rally Hits Fresh Highs, Fueled By Micron Earnings, China Stimulus: Weekly Review
September 27, 2024
The S&P 500 hit record highs, fueled by Micron and Chinese stimulus.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Interesting Technical Analysis finding for AMGEN INC (NASDAQ:AMGN)
September 20, 2024
NASDAQ:AMGN Shows Potential for a Breakout.
Via
Chartmill
Where Will Amgen Be in 5 Years?
September 20, 2024
There are plenty of ongoing positive developments with the biotech giant.
Via
The Motley Fool
Behind the Scenes of Amgen's Latest Options Trends
September 19, 2024
Via
Benzinga
Taiwan Semiconductor, American Tower, Trane Technologies And A Health Care Stock On CNBC's 'Final Trades'
September 26, 2024
Analyst Stephen Weiss of Short Hills Capital Partners said he still finds Taiwan Semiconductor Manufacturing Company cheap.
Via
Benzinga
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
September 25, 2024
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in the atopic dermatitis and myasthenia gravis markets. Attention shifts to...
Via
Benzinga
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
September 25, 2024
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent...
Via
Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
September 24, 2024
Regeneron filed an appeal after a court's decision, which was issued under seal.
Via
Benzinga
2 Weight-Loss Stocks That Could Rocket Higher This Year
September 24, 2024
Upcoming clinical trial results could push these stocks through the roof before 2024 is finished.
Via
The Motley Fool
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
September 23, 2024
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year.
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
September 23, 2024
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off.
Via
Investor's Business Daily
Amgen vs. Viking Therapeutics: What's the Better GLP-1 Stock to Buy?
September 23, 2024
These two stocks could be rivals in the intense GLP-1 space in the future.
Via
The Motley Fool
Can These 5 Assets Skyrocket Your Portfolio?
September 22, 2024
Are Verizon, Amazon, Cisco, Amgen, and the S&P Biotech Bull 3X Shares ETF poised to make your portfolio skyrocket? In this video, I take a closer look.
Via
Talk Markets
Topics
ETFs
Stocks
Exposures
US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
September 18, 2024
Via
Benzinga
The Bull Market Strengthened, Let The Naysayers Say Nay...
September 15, 2024
Being able to recite the potential problems in the world does not make you a good investor.
Via
Talk Markets
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help...
Via
Talk Markets
Topics
ETFs
2 Unstoppable Growth Stocks to Buy Right Now for Less Than $500
September 13, 2024
Growth-oriented businesses can make excellent additions to a well-diversified portfolio.
Via
The Motley Fool
< Previous
1
2
3
4
5
6
7
8
9
...
46
47
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.